Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Recruiting No phase listed Observational

CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness

NCT04504955
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Observational Non-Interventional Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777, Placebo
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 28, 2026, 7:01 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Terminated No phase listed Observational

Dupilumab Phase 4 Study

NCT03411837
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
46 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Treatment Resistant Dermatitis TaroIIR

NCT03050294
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Phone calls, Desoximetasone 0.25% spray
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Study of Apremilast in Atopic or Contact Dermatitis

NCT00931242
View directory record Official record
Conditions
Atopic Dermatitis, Allergic Contact Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Oral DS107 in Moderate to Severe Atopic Dermatitis

NCT02211417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral DS107, Placebo
Drug
Lead sponsor
Dignity Sciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Arlington Heights, Illinois • West Dundee, Illinois • Warren, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 28, 2026, 7:01 AM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Not applicable Interventional

Text Messaging and Atopic Dermatitis

NCT01216059
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Text message to cell phone
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Oct 28, 2026, 7:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sebum Collection and Skin Barrier Function Analysis

NCT03112876
View directory record Official record
Conditions
Smoking, Acne, Atopic Dermatitis, Aging
Interventions
Skin Surface Lipid Collection and Skin Barrier Function
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 28, 2026, 7:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Varicella Vaccination in Children With Atopic Dermatitis

NCT00406081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 36 Months
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Not applicable Interventional

Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema

NCT03619161
View directory record Official record
Conditions
Eczema, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
Interventions
Bubbles, Bleach and Bubbles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Months to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101
View directory record Official record
Conditions
Nasal Allergy
Interventions
Nasal lavage, Nasal allergen challenge, Epicutaneous skin testing, Peripheral blood, Montelukast 10Mg Tablet, Placebo Oral Tablet
Procedure · Drug
Lead sponsor
Mitchell Grayson
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 28, 2026, 7:01 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

NCT01905631
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Aurstat Anti-Itch Hydrogel (Aurstat)
Drug
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 28, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

NCT05932654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BSI-045B
Drug
Lead sponsor
Biosion, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
17
States / cities
Fountain Valley, California • Fremont, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 7:01 AM EDT
Terminated Not applicable Interventional

Health Literacy for Children With Atopic Dermatitis and Their Caregivers

NCT01138761
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nurse instruction
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 7 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 28, 2026, 7:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
JNJ-95597528, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 7:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT05859724
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NM26-2198, Placebo
Biological · Other
Lead sponsor
Yellow Jersey Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fountain Valley, California • Glendale, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 7:01 AM EDT